• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>International Journal of Molecular Sciences >Primary Study for the Therapeutic Dose and Time Window of Picroside II in Treating Cerebral Ischemic Injury in Rats
【2h】

Primary Study for the Therapeutic Dose and Time Window of Picroside II in Treating Cerebral Ischemic Injury in Rats

机译：Piccoside II治疗大鼠脑缺血损伤的治疗剂量和时间窗的初步研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The aim of this study was to explore the optimal therapeutic dose and time window of picroside II for treating cerebral ischemic injury in rats according to the orthogonal test. The middle cerebral artery occlusion (MCAO) models were established by intraluminally inserting a thread into middle cerebral artery (MCA) from left external carotid artery (ECA). The successful rat models were randomly divided into 16 groups according to the orthogonal layout of [L16(45)] and treated by injecting picroside II intraperitoneally with different doses at various times. The neurological behavioral function was evaluated by Bederson’s test and the cerebral infarction volume was measured by tetrazolium chloride (TTC) staining. The expressions of neuron specific enolase (NSE) and neuroglial mark-protein S-100 were determined by immunohistochemisty assay. The results indicated that the optimal compositions of the therapeutic dose and time window of picroside II in treating cerebral ischemic injury were ischemia 1.5 h with 20 mg/kg body weight according to Bederson’s test, 1.0 h with 20 mg/kg body weight according to cerebral infarction volume, 1.5 h with 20 mg/kg body weight according to the expressions of NSE and S-100 respectively. Based on the principle of the minimization of medication dose and maximization of therapeutic time window, the optimal composition of the therapeutic dose and time window of picroside II in treating cerebral ischemic injury should be achieved by injecting picroside II intraperitoneally with 20 mg/kg body weight at ischemia 1.5 h.
机译：这项研究的目的是根据正交试验，探索苦瓜苷II治疗大鼠脑缺血损伤的最佳治疗剂量和时间窗。通过腔内从左颈外动脉（ECA）向内大脑中动脉（MCA）插入一根线，建立大脑中动脉闭塞（MCAO）模型。根据[L16（4 5 ）]的正交排列，将成功的大鼠模型随机分为16组，并在不同时间腹膜内注射不同剂量的苦味子苷II。神经行为学功能通过Bederson检验进行评估，脑梗死体积通过氯化四氮唑（TTC）染色进行测量。免疫组化法检测神经元特异性烯醇化酶（NSE）和神经胶质标记蛋白S-100的表达。结果表明，根据贝德森氏试验，吡咯类糖苷II治疗脑缺血损伤的最佳剂量和时间窗组成为：缺血1.5 h，根据Bederson检验为20 mg / kg体重； 1.0 h，20 mg / kg体重，根据脑缺血根据NSE和S-100的表达，分别以20 mg / kg体重的1.5 h梗塞体积。基于最小剂量和最大治疗时间窗的原则，应通过腹膜内注射20 mg / kg体重的苦味苦苷II来获得苦味苷苦味苷II治疗脑缺血性损伤的最佳剂量和时间范围。在局部缺血1.5小时。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号